OBJECTIVES: This retrospective chart review aimed to quantify hospitalisations and costs among adult R/R ALL patients treated with current salvage chemotherapies in France. METHODS: Eligible patients were aged ≥18 years and hospitalised from 2003-2013 for Ph-negative R/R ALL. They were relapsed with first remission lasting <12 months, relapsed after first salvage therapy, relapsed any time after HSCT, or refractory to initial or salvage therapy. Data were collected from the index date (first diagnosis of R/R ALL) until death or loss to follow-up. The salvage chemotherapy period was defined as the first chemotherapy hospitalisation after the index date to the earliest of mean time to HSCT, death, loss to follow-up, or last chemotherapy dose plus 30 days. The primary endpoint was the percent of time in the hospital during the salvage chemotherapy period. A key secondary endpoint was total costs from index date to death. Hospitalisations and costs associated with HSCT were excluded. RESULTS: Thirty-three patients were included, with mean age of 49 years (range 19-75). The mean proportion of time patients spent in the hospital during the salvage chemotherapy period was 46% (95%CI: 34%-57%). The mean number of inpatient hospitalisations during the salvage chemotherapy period was 2.15 (1.5), and mean length stay was 17 (15) days. During the salvage chemotherapy period, the mean (SD) cost per hospitalisation was €31,067 (€4,850) and the mean hospitalisation cost per patient was €66,842 (€46,268). From the index date to death, there was a mean of 3.67 inpatient hospitalizations, 4.27 day hospitalizations, and 0.7 outpatient visits. Corresponding mean (SD) costs per hospitalisation were €28,832 (€8,867), €674 (0), and €394 (0) respectively, for a total cost per patient of €108,967. CONCLUSIONS: Adult patients receiving salvage chemotherapy for R/R ALL spend approximately half their time in the hospital, which is associated with large reimbursement costs in France.